GENESIS Pharma S.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GENESIS Pharma S.A.
Henlius Sees Revenues Soar In 2022, Q1 2023, As New Plant Bears Fruit
Chinese player Shanghai Henlius Biotech has published unaudited financial results for the first three months of 2023, in the wake of its 2022 annual report.
Strides And Orbicular Agree Alliance To Develop Nasal Sprays
Strides has agreed to partner with Orbicular to develop four nasal sprays targeting a combined market worth more than $400m for markets including Europe and the US.
Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.
Chinese Biotechs Reshuffle Pipeline, Cut Headcount To Stay Afloat
Two bioventures in China have jettisoned immuno-oncology assets, including PD-1/L1- and CD47-targeting agents, while four other firms have disclosed shifts in R&D priorities and employee lay-offs as they deal with challenging conditions.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.